Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Hultberg, Anna ^a   Temperton, Nigel J ^b,c   Rosseels, Valérie ^d   Koenders, Mireille ^a   Gonzalez Pajuelo, Maria ^e   Schepens, Bert ^f,g   Ibañez, Lorena Itatí ^f,g   Vanlandschoot, Peter ^e   Schillemans, Joris ^h   Saunders, Michael ^e   Weiss, Robin A ^b   Saelens, Xavier ^f,g   Melero, José A ⁱ   Verrips, C Theo ^a   van Gucht, Steven ^d   de Haard, Hans J ^a,e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^d SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^e ABLYNX NV   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^g GHENT UNIVERSITY   (Belgium)

^h UTRECHT UNIVERSITY   (Netherlands)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN; HEAVY CHAIN ANTIBODY FRAGMENT; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INFLUENZA B12 HEAVY CHAIN ANTIBODY FRAGMENT; INFLUENZA C8 HEAVY CHAIN ANTIBODY FRAGMENT; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RABIES C12 HEAVY CHAIN ANTIBODY FRAGMENT; RABIES E6 HEAVY CHAIN ANTIBODY FRAGMENT; RABIES E8 HEAVY CHAIN ANTIBODY FRAGMENT; RABIES F8 HEAVY CHAIN ANTIBODY FRAGMENT; RABIES H7 HEAVY CHAIN ANTIBODY FRAGMENT; RESPIRATORY SYNCYTIAL VIRUS 17 HEAVY CHAIN ANTIBODY FRAGMENT; RESPIRATORY SYNCYTIAL VIRUS C4 HEAVY CHAIN ANTIBODY FRAGMENT; RESPIRATORY SYNCYTIAL VIRUS D3 HEAVY CHAIN ANTIBODY FRAGMENT; RESPIRATORY SYNCYTIAL VIRUS E4 HEAVY CHAIN ANTIBODY FRAGMENT; RESPIRATORY SYNCYTIAL VIRUS NR1 HEAVY CHAIN ANTIBODY FRAGMENT; RESPIRATORY SYNCYTIAL VIRUS NR4 HEAVY CHAIN ANTIBODY FRAGMENT; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL THERAPY; ARTICLE; ARTIODACTYLA; BINDING SITE; CONTROLLED STUDY; CROSS PROTECTION; DRUG POTENCY; DRUG PROTEIN BINDING; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLUENZA VIRUS A H5N1; LLAMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PSEUDOTYPING; RABIES VIRUS; RECEPTOR BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CROSS REACTION; DOSE RESPONSE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; VIRUS;

LAMA (MAMMAL); RABIES VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIVIRAL AGENTS; CAMELIDS, NEW WORLD; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES; GENOTYPE; IMMUNOGLOBULIN HEAVY CHAINS; INFLUENZA A VIRUS, H5N1 SUBTYPE; LYSSAVIRUS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL PROTEINS; VIRUSES;

EID: 79953654632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017665     Document Type: Article

References (35)

1. Colman PM, (2009) New antivirals and drug resistance. Annu Rev Biochem 78: 95-118.
2. Sheldon J, Soriano V, (2008) Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 61: 766-768.
3. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, et al. (2008) Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 82: 12069-12081.
4. Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, et al. (2008) Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol 82: 9753-9764.
5. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, et al. (2006) Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 24: 4130-4137.
6. Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P, (2009) Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology 49: 39-49.
7. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, et al. (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54: 1856-1866.
8. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, et al. (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 56: 303-317.
9. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
10. Harmsen MM, De Haard HJ, (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77: 13-22.
11. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, et al. (2005) Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding kinetics and Binding Valence on Viral Neutralization. J Mol Biol 350: 126-144.
12. Beeler JA, Coelingh K, (1989) Neutralization epitopes of the F protein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63: 2941-2950.
13. Crowe JE, Firestone CY, Crim R, Beeler JA, Coelingh KL, et al. (1998) Monoclonal antibody-resistant mutants selected with a Respiratory Syncytial virus-neutralizing epitope on the Fusion (F) glycoprotein. Virol 252: 373-375.
14. Wu SJ, Schmidt A, Beil EJ, Day ND, Branigan PJ, et al. (2007) Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J Gen Virol 88: 2719-2723.
15. López JA, Bustos R, Orvell C, Berois M, Arbiza J, et al. (1998) Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72: 6922-6928.
16. Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, et al. (2007) A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Resp. Viruses 1: 105-112.
17. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
18. Wandeler AI, Matter HC, Kappeler A, Budde A, (1993) The ecology of dogs and canine rabies: a selective review. Rev Sci Tech 12: 51-71.
19. Fooks AR, Brookes SM, Johnson N, McElhinney LM, Hutson AM, (2003) European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 131: 1029-1039.
20. Montaño-Hirose JA, Lafage M, Weber P, Badrane H, Tordo N, et al. (1993) Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice. Vaccine 11: 1259-1266.
21. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, et al. (1997) Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus. J Infect Dis 176: 1215-1224.
22. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, et al. (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 104: 18363-18370.
23. DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, et al. (2004) Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 190: 975-978.
24. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 6: 615-622.
25. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, et al. (2005) Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants. J Virol 79: 9062-9068.
26. Schofield DJ, Stephenson JR, Dimmock NJ, (1997) Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol 78: 2431-2439.
27. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP Jr, et al. (2009) Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 106: 7385-7390.
28. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, et al. (2006) Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A103: 4586-4591.
29. Conrath KE, Lauwereys M, Wyns L, Muyldermans S, (2001) Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs. JBC 276: 7346-7350.
30. Saerens D, Ghassabeh GH, Muyldermans S, (2008) Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 8: 600-608.
31. Corral T, Ver LS, Mottet G, Cano O, García-Barreno B, et al. (2007) High level expression of soluble glycoproteins in the allantoic fluid of embryonated chicken eggs using a Sendai virus minigenome system. BMC Biotechnol 7: 17.
32. García-Barreno B, Palomo C, Peñas C, Delgado T, Perez-Breña P, et al. (1989) Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63: 925-932.
33. Le Roux I, Van Gucht S, (2008) Two cases of imported canine rabies in the Brussels area within six months time. WHO Rabies Bulletin 32: Quarter 1.
34. Bourhy H, Kissi B, Lafon M, Sacramento D, Tordo N, (1992) Antigenic and molecular characterization of bat rabies virus in Europe. J Clin Microbiol 30: 2419-2426.
35. Wiktor TJ, Koprowski H, (1978) Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci USA 75: 3938-3942.